Why did reported EPS drop so sharply while adjusted EPS was less affected?

Reported diluted EPS fell 21% to $0.62, largely due to a one-time $1.35 billion acquired IPR&D charge from the 3SBio in-licensing agreement, which reduced EPS by about $0.20 in the full year. Adjusted EPS excludes items such as amortization of intangibles, acquisition-related items, and certain significant items, so it presents a more normalized view of operating performance, though it still declined 18% to $0.87.

Is Pfizer's revenue outlook changing for 2025?

No. Full-year 2025 revenue guidance was reaffirmed at $61.0 to $64.0 billion. Guidance absorbs the impact of tariffs from China, Canada, and Mexico and an expected approximately $0.4 billion unfavorable impact from generic and biosimilar competition. It does not assume any business development transactions not completed as of November 4, 2025.

What is driving the EPS guidance increase?

Management attributed the raised and narrowed Adjusted EPS range of $3.00–$3.15 to solid year-to-date performance, progress on cost-improvement initiatives, and an improved effective tax rate on Adjusted income, now expected at about 11% versus about 13% previously. Adjusted R&D expense guidance was also lowered to $10.0–$11.0 billion from $10.4–$11.4 billion.

Will Pfizer resume share buybacks, and how is it allocating capital?

Not in 2025. No repurchases have been completed year to date, and guidance assumes none. Pfizer has $3.3 billion remaining on its authorization and paid $7.3 billion in dividends through the first nine months. Management says it will continue to de-lever prudently while keeping flexibility for value-creating business development, including the pending Metsera acquisition, which may be financed with cash and new debt.

What are the main risks to Pfizer's near-term growth?

Key risks include continued decline in COVID-19 products (Paxlovid and Comirnaty) as infection rates and vaccine recommendations narrow, generic and biosimilar erosion, U.S. drug pricing and tariff policy, and execution risk on acquisitions. The Metsera deal is also contested after Novo Nordisk made a competing proposal on October 25, and Pfizer has filed lawsuits to enforce the merger agreement.

PFE 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed November 4, 2025. Cited figures are marked; the original filing is the authoritative source.

Pfizer reported third-quarter 2025 results on November 4, 2025 that were mixed on the top line but solid on earnings.

Revenues were $16.7 billion^a, down 6% reported and down 7% operationally, driven by a steep decline in COVID-19 products (Paxlovid down 55% operationally, Comirnaty down 20%). Excluding COVID-19 products, the non-COVID portfolio grew 4% operationally, led by Eliquis (up 22% operationally), Nurtec ODT/Vydura (up 22%), and Vyndaqel family (up 7%). Reported diluted EPS fell 21% to $0.62, reflecting a one-time $1.35 billion acquired IPR&D charge tied to the 3SBio in-licensing deal, while Adjusted diluted EPS was $0.87, down 18% year over year.

Management reaffirmed full-year 2025 revenue guidance of $61.0 to $64.0 billion^b and raised and narrowed Adjusted diluted EPS guidance to $3.00 to $3.15, up from $2.90 to $3.10. The EPS increase was supported by year-to-date performance, cost-reduction progress, and an improved effective tax rate assumption of about 11%, down from 13%. Management also highlighted a landmark agreement with the U.S. government on drug pricing and tariff relief, and early FTC clearance for the pending Metsera acquisition, which has since been contested by a competing Novo Nordisk proposal.

For investors, the key tensions are the structural erosion of COVID-19 revenue, the pressure from upcoming generic and biosimilar competition, and the capital allocation trade-off. Pfizer has paid $7.3 billion^c in dividends, has made no share repurchases in 2025, and is guiding to none. Management is prioritizing de-leveraging while keeping room for business development, including the Metsera deal, which is expected to be financed with cash and new debt.

02—Key points

Key Highlights

Q3 2025 revenues fell 6% to $16.7 billion (-7% operationally), mainly from COVID-19 product declines, while non-COVID revenue grew 4% operationally.
Reported diluted EPS was $0.62 (down 21%), depressed by a $1.35 billion acquired IPR&D charge from the 3SBio in-licensing deal; Adjusted diluted EPS was $0.87 (down 18%).
Full-year 2025 revenue guidance was reaffirmed at $61.0–$64.0 billion, while Adjusted diluted EPS guidance was raised and narrowed to $3.00–$3.15 from $2.90–$3.10.
The effective tax rate assumption on Adjusted income was lowered to about 11% from about 13%, a key driver of the EPS guidance increase.
Eliquis (+22% operationally), Nurtec ODT/Vydura (+22%), and Vyndaqel family (+7%) led growth, offsetting Paxlovid (-55%) and Comirnaty (-20%) declines.
Pfizer reached a landmark agreement with the U.S. government on drug pricing and TrumpRx.gov participation, with a three-year tariff grace period for Section 232 products.
No share repurchases were made in 2025 and none are assumed in guidance; $3.3 billion remains authorized, and the company prioritizes de-leveraging and business development.

03—Questions

Frequently Asked Questions

Why did reported EPS drop so sharply while adjusted EPS was less affected?
Reported diluted EPS fell 21% to $0.62, largely due to a one-time $1.35 billion acquired IPR&D charge from the 3SBio in-licensing agreement, which reduced EPS by about $0.20 in the full year. Adjusted EPS excludes items such as amortization of intangibles, acquisition-related items, and certain significant items, so it presents a more normalized view of operating performance, though it still declined 18% to $0.87.
Is Pfizer's revenue outlook changing for 2025?
No. Full-year 2025 revenue guidance was reaffirmed at $61.0 to $64.0 billion. Guidance absorbs the impact of tariffs from China, Canada, and Mexico and an expected approximately $0.4 billion unfavorable impact from generic and biosimilar competition. It does not assume any business development transactions not completed as of November 4, 2025.
What is driving the EPS guidance increase?
Management attributed the raised and narrowed Adjusted EPS range of $3.00–$3.15 to solid year-to-date performance, progress on cost-improvement initiatives, and an improved effective tax rate on Adjusted income, now expected at about 11% versus about 13% previously. Adjusted R&D expense guidance was also lowered to $10.0–$11.0 billion from $10.4–$11.4 billion.
Will Pfizer resume share buybacks, and how is it allocating capital?
Not in 2025. No repurchases have been completed year to date, and guidance assumes none. Pfizer has $3.3 billion remaining on its authorization and paid $7.3 billion in dividends through the first nine months. Management says it will continue to de-lever prudently while keeping flexibility for value-creating business development, including the pending Metsera acquisition, which may be financed with cash and new debt.
What are the main risks to Pfizer's near-term growth?
Key risks include continued decline in COVID-19 products (Paxlovid and Comirnaty) as infection rates and vaccine recommendations narrow, generic and biosimilar erosion, U.S. drug pricing and tariff policy, and execution risk on acquisitions. The Metsera deal is also contested after Novo Nordisk made a competing proposal on October 25, and Pfizer has filed lawsuits to enforce the merger agreement.

04—Continue

← View all 8-K filings